Table 2. Baseline demographic characteristics of 52 patients treated with lapatinib plus capecitabine.

Characteristic	No. of patients (%)
Age (years)
Median	50
Range	26–71
Menopausal	24 (46.2)
Stage of disease
Stage IIIB/IIIC	1 (1.9)
Stage IV	51 (98.1)
Hormone receptor status
ER+ and/or PR+	25 (48.1)
ER– and PR–	26 (50.0)
Unknown	1 (1.9)
ECOG PS
0	30 (57.7)
1	22 (42.3)
Metastatic sites
Visceral and/or nonvisceral	41 (78.8)
Nonvisceral only	11 (21.2)

Data are presented as number of patients, with the percentage in parentheses, except for age. ER+, estrogen receptor–positive; PR+, progesterone receptor–positive; ER–, estrogen receptor–negative; PR–, progesterone receptor–negative; ECOG, Eastern Cooperative Oncology Group; PS, performance status.